upper waypoint

How 'The Year of Ozempic' Transformed Obesity Treatment… and Much More

Save ArticleSave Article
Failed to save article

Please try again

This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France. (SEBASTIEN BOZON/AFP via Getty Images)

In a recent piece for the New Yorker called “The Year of Ozempic,” journalist and physician Dhruv Khullar writes that “we may look back on new weight-loss drugs as some of the greatest advances in the annals of chronic disease.” But the drugs don’t work for everyone, and there are ongoing questions about side effects, costs and availability. We’ll talk with Khullar about his piece and check in with UCSF weight loss doctor Diana Thiara about what we’ve learned about drugs like Ozempic and Wegovy over the past year.

Guests:

Dhruv Khullar, contributing writer, The New Yorker; practicing physician, Weill Cornell Medicine; assistant professor, Weill Cornell Medical College.<br />

Diana Thiara, medical director, UCSF Weight Loss Management Program

Sponsored

lower waypoint
next waypoint